SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower
growth from syringes

EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower
growth from syringes

14-May-2024 / 18:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

SCHOTT Pharma see FY 25 impacted by slower growth from syringes

For its fiscal year 2024/2025, beginning 1st October 2024, the company is
forecasting a revenue growth in a high single-digit to a low double-digit
percentage range, which deviates from the current market consensus. Due to
the revenue growth that is lower than previously expected, the EBITDA margin
expansion will be weaker than currently expected in the market.

These forecasts are based on constant currencies.

The reason for the expected development in fiscal year 2024/2025 is a lower
demand for syringes of a large customer.

Despite this temporary effect, the company confirms its mid-term forecast.
The company also confirms its forecast for the current fiscal year.

Investor contact

Jasko Terzic, CFA

Senior Investor Relations Manager

E-Mail: ir.pharma@schott.com

Press contact

Joana Kornblum

Media Relations

Tel.: +49 151/29223552

E-Mail: joana.kornblum@schott.com


End of Inside Information

---------------------------------------------------------------------------

14-May-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SCHOTT Pharma AG & Co. KGaA
                   Hattenbergstraße 10
                   55122 Mainz
                   Germany
   ISIN:           DE000A3ENQ51
   WKN:            A3ENQ5
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate
                   Exchange; Vienna Stock Exchange
   EQS News ID:    1902981

End of Announcement EQS News Service
---------------------------------------------------------------------------

1902981 14-May-2024 CET/CEST